Beam Therapeutics Inc. (BEAM) RBC Capital Markets International Healthcare Convention 2026 Might 20, 2026 10:30 AM EDT
Firm Individuals
John Evans – CEO & Director
Convention Name Individuals
Luca Issi – RBC Capital Markets, Analysis Division
Presentation
Luca Issi
RBC Capital Markets, Analysis Division
Capital Market. As we speak is a superb privilege to have Beam as a part of our 2026 International Healthcare Convention. Representing the corporate, we have now John Evans, Chief Govt Officer. John, thanks a lot for becoming a member of us. How are you doing at the moment?
John Evans
CEO & Director
Doing very nicely. Thanks, Luca.
Query-and-Reply Session
Luca Issi
RBC Capital Markets, Analysis Division
Nice. Lengthy listing of questions right here, however perhaps earlier than we go into specifics, it will be nice in case you can perhaps begin a little bit bit massive image about what progress has the group made not too long ago and sort of what’s forward right here for Beam?
John Evans
CEO & Director
Nice. Sure. So it is nice to see you all. So Beam Therapeutics is a next-generation gene modifying firm. We’re engaged on a brand new type of CRISPR referred to as base modifying. And so this permits us to make single letter modifications in genes on a everlasting foundation without having to make a double-stranded break. This lets us make many extra sorts of edits, extra therapeutic edits, extra exact edits, together with doing issues like correcting mutations again to regular moderately than simply knocking issues out. We’re pursuing this in a wide range of totally different locations, ex vivo and in hematology for the therapy of sickle cell illness. Our lead program, Risto-cel, is shifting in direction of market, and we’ll speak a little bit bit about that. I am positive we’ll have a BLA submitting as quickly as the tip of this 12 months, adopted by a analysis effort to maneuver sickle remedy in vivo utilizing a few of our LNP capabilities.
